Posted by Michael Wonder on 29 Sep 2024
Dupixent (dupilumab) approved in the US as the first ever biologic medicine for patients with COPD
27 September 2024 - Following recent approvals in the EU and China, the US approval is based on two landmark Phase 3 trials that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo.
Regeneron Pharmaceuticals and Sanofi today announced that the US FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease and an eosinophilic phenotype.
